AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Girdin

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q3V6T2

UPID:

GRDN_HUMAN

Alternative names:

Akt phosphorylation enhancer; Coiled-coil domain-containing protein 88A; G alpha-interacting vesicle-associated protein; Girders of actin filament; Hook-related protein 1

Alternative UPACC:

Q3V6T2; A1IGE7; B7ZM78; C9JG83; Q53SF1; Q581G3; Q5HYD0; Q7Z339; Q7Z3C5

Background:

Girdin, also known as Akt phosphorylation enhancer, plays a pivotal role in cell migration by modulating G proteins and enhancing EGFR signaling. It is crucial for neuron integration during adult neurogenesis, influencing dendritic development and synapse formation. Girdin's interaction with G(i) alpha subunits and inhibition of G(s) subunit alpha GNAS underscores its importance in cellular processes, including actin cytoskeleton integrity and cell proliferation.

Therapeutic significance:

Linked to PEHO-like syndrome, Girdin's involvement in severe neurological disorders highlights its potential as a therapeutic target. Understanding Girdin's role could open doors to novel strategies for treating conditions characterized by brain atrophy, seizures, and cognitive delay.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.